

2023 Annual General Meeting Chairman's Address

Good morning shareholders,

My name is Alex Ding, and I am the non-executive independent Chairman of Bio-Gene Technology Limited. I would like to welcome you to the 2023 Annual General Meeting of the Company. This meeting is being held virtually and also physically at Level 14, 333 Collins Street, Melbourne, as permitted by the Company's Constitution and the Corporations Act. I am dialing in from Sydney.

Before we commence with the formalities of the meeting, I would like to introduce you to the other directors of the Company:

- Mr Andrew Guthrie;
- Mr Chris Ramsey;
- Mr Tim Grogan; and
- Mr Peter May.

Except for Mr Chris Ramsey, who is dialling in from Brisbane, all other directors are in the meeting room in Melbourne.

Mr Roger McPherson, the Company's current company secretary, is also in the meeting room in Melbourne.

I also advise that Mr Wayne Tarrant from our auditors JTP Assurance is in attendance today and available to take questions from shareholders.

I note that my appointment as Chairman followed the retirement of previous Chairman Robert Klupacs. On behalf of the Company, I thank Robert for his dedication and commitment to steering the Company for eight years.

Before we move to the formal matters to be considered at this meeting, I would like to report on a year of significant progress and change for the Company, positioning Bio-Gene for the next pivotal stage of commercialising our active ingredients Qcide® and Flavocide®.

Over the past twelve months we have made good progress in developing the next generation of novel insecticides, collaborating with our global commercial and research partners to solve the global problem of increasing insecticide resistance. Current chemistry is no longer proving effective to control pests and disease carrying vectors, while at the same time, the inhabitable environment for pests is growing due to changing weather patterns.

According to the World Health Organisation, more than half the world is at risk of vector-borne diseases. Mosquitos are by far the most common, and deadliest vector; malaria alone infected close to 250 million people in 2021, killing over 600,000 people in 2021¹. And in Australia, we are seeing a concerning increase in cases of the deadly Murray River encephalitis. The global mosquito control market is worth over \$840 million per year, and by 2026, public health agencies and chemical companies will spend 41% more on controlling mosquitoes than they did in 2021².

After three decades without any major breakthroughs in public health insecticides, Bio-Gene's unique and naturally derived chemical compounds are a game changer, delivering the first new chemistry in 30 years that can effectively control pests and insects while overcoming resistance, and with low toxicity for humans and the environment.

2023 has been an important inflection year for Bio-Gene with changes to the Executive and Board to support the Company's pathway to commercialisation. We welcomed Christopher Ramsey to our Board and Tim Grogan as Bio-Gene's new Managing Director and Chief Executive Officer. Tim brings a wealth of relevant experience and expertise to Bio-Gene. Throughout his career, he has demonstrated an ability to take new chemically-based technologies to commercial use in the market through focusing on the best path to market, forging and fostering strategic partnerships, and delivering on key milestones.

The skill set we have obtained from this new appointment aligns with our objective of taking Qcide and Flavocide to registration for commercial end-use in the major relevant markets for insecticide needs. We have strengthened our commercial capability and our ability to execute at a crucial development and growth stage for the Company and enhanced our skills to support future commercialisation.

I would also like to take this opportunity to thank you, our shareholders, for your continued support and confidence in the Company. Bio-Gene's products continue to receive strong validation from our global partners, and we continue to see expanding interest and opportunities to expand our commercial partnerships.

We look forward to continuing to update you as we commercialise the Company's key assets Qcide and Flavocide and hope you will remain with us on that journey.

I'll now hand over to CEO Tim Grogan to brief you on the key developments during the period and to outline our strategic objectives moving forward.

Approved for release by the Board of Directors

- ENDS -

¹ World Health Organization World Malaria Report, 2022

² Global Mosquito Control Professional Survey Report 2021, Forecast to 2026

For further information, please contact:

Bio-Gene Technology Limited:
E: bgt.info@bio-gene.com.au

Adrian Mulcahy, Investor Relations
E: adrian.mulcahy@automicgroup.com.au
M: 0438 630 422

Tristan Everett, Media Relations
E: tristan.everett@automicgroup.com.au
M: 0403 789 096

About Bio-Gene Technology Ltd

Bio-Gene is an Australian agtech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones.

Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection, grain storage, public health and consumer products. Bio-Gene's aim is to develop and commercialise a broad portfolio of targeted insect control and pest management solutions.

Qcide® and Flavocide® are trademarks of Bio-Gene Technology Limited.